

Article

Not peer-reviewed version

Quantification of Analgesic and Anti-inflammatory Lipid Mediators in Long-Term Cryopreserved and Freeze-Dried Preserved Human Amniotic Membrane

Vladimír Vrkoslav[†], Ingrida Smeringaiova[†], Natalia Smorodinova[†], Alzbeta Svobodova, [Stepan Strnad](#), [Catherine Joan Jackson](#), Jan Burkert, [Katerina Jirsova](#)^{*,†}

Posted Date: 26 May 2023

doi: 10.20944/preprints202305.1876.v1

Keywords: amniotic membrane allografts; cryopreserved amniotic membrane; lyophilization; freeze-dried amniotic membrane; N-acylethanolamines; palmitoylethanolamide; tissue banking; mass spec-trometry



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Quantification of Analgesic and Anti-Inflammatory Lipid Mediators in Long-Term Cryopreserved and Freeze-Dried Preserved Human Amniotic Membrane

Vladimir Vrkoslav ^{1,†}, Ingrida Smeringaiova ^{2,†}, Natalia Smorodinova ^{2,3,†}, Alzbeta Svobodova ⁴, Stepan Strnad ¹, Catherine Joan Jackson ⁵, Jan Burkert ⁶ and Katerina Jirsova ^{2,*}

¹ The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; vrkoslav@uochb.cas.cz (V.V.); stepan.strnad@uochb.cas.cz (S.S)

² Laboratory of the Biology and Pathology of the Eye, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; smer.inga@gmail.com (I.S.); natalia.smorodinova@lf1.cuni.cz (N.S.)

³ Institute of Histology and Embryology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

⁴ 2nd Department of Surgery – Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; alzbeta.svo@seznam.cz

⁵ Department of Medical Biochemistry, Oslo University Hospital and Institute of Oral Biology, University of Oslo, Oslo, Norway; catherinejoan.jackson@gmail.com

⁶ Department of Transplantation and Tissue Bank, University Hospital in Motol, Prague, Czech Republic; jan.burkert@fnmotol.cz

* Correspondence: katerina.jirsova@lf1.cuni.cz; Tel.: +420 224 968 006

† These authors contributed equally to this work.

Abstract: To compare concentrations of endogenous N-acylethanolamines (NAEs) lipid mediators palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and anandamide (AEA) in fresh, decontaminated, cryopreserved and freeze-dried amniotic membrane (AM) allografts. Thereby determining whether AM's analgesic and anti-inflammatory efficiency related to NAEs persists during storage. The concentrations of NAEs were measured using ultra-high-performance liquid chromatography-tandem mass spectrometry. Indirect fluorescent immunohistochemistry was used to detect the PEA PPAR α receptor. The concentrations of PEA, OEA, and AEA were significantly higher after decontamination. A significant decrease was found in cryopreserved AM compared to decontaminated tissue for PEA but not for OEA and AEA. However, significantly higher values for all NAEs were detected in cryopreserved samples compared to fresh tissue before decontamination. The freeze-dried AM had similar values to decontaminated AM with no statistically significant difference. The nuclear staining of PPAR α receptor was clearly visible in all specimens. The stability of NAEs in AM after cryopreservation was demonstrated under tissue bank storage conditions. However, a significant decrease, but still higher concentration of PEA compared to fresh not decontaminated tissue was found in cryopreserved, but not freeze-dried AM. Results indicate that NAEs persist during storage in levels sufficient for the analgesic and anti-inflammatory effects of AM allografts.

Keywords: amniotic membrane allografts; cryopreserved amniotic membrane; lyophilization; freeze-dried amniotic membrane; N-acylethanolamines; palmitoylethanolamide; tissue banking; mass spectrometry

1. Introduction

The human amniotic membrane (AM) has long been used to treat wounds in ophthalmology, dermatology and surgery [1]. The therapeutic effect of AM allografts originates in the high content

of growth factors, cytokines, extracellular matrix components, and the presence of pluripotent stem cells [2,3]. AM is typically obtained from the placenta after caesarean section, prepared by manual separation from the underlying chorionic membrane, cleaned, decontaminated, and stored. For transplantation purposes serological tests for potentially transmissible diseases (human immunodeficiency virus, hepatitis B and C viruses, and syphilis) must be negative both at the time of tissue collection and when repeated after 180 days [4,5].

Based on the number of papers published on the use of placental membranes for grafting in PubMed database, the most common storage method for AM is cryopreservation [6–8]. Reports over the last few years suggest that cryopreservation has been slowly supplanted by freeze-dry methods (lyophilized, vacuum freeze dehydrated), which are particularly common in wound healing treatment [9–11]. However, for ophthalmosurgery both storage methods for AM are used equally [10,12,13].

The method of AM processing may affect its therapeutic properties, i.e. induction of granularization and re-epithelialization [14], reduction of fibrosis [15], pain [16,17], inflammation [18], antimicrobial [19] and antiviral [20] properties and also pro-angiogenic [21,22] and anti-angiogenic [23,24] features.

Cryopreservation preserves the biological activity and structure of tissue. Before cryopreservation storage, AM is chemically decontaminated and usually placed in a mixture of culture medium and glycerol [25,26].

Freeze-dried AM is prepared in a lyophilizer, where the tissue is gently dried using a high vacuum to a final water content of 5–10% [27]. The crucial advantage of freeze-drying compared to cryopreservation is that AM allografts can be stored and transported at room temperature. Disadvantages include tissue destruction, a decrease of protein levels and activity if gamma-sterilization is used for terminal sterilization [28–31]. Recently, radiation has been substituted for a less destructive chemical decontamination technique under clean room conditions. Thus, the AM structure is preserved with no serious structure and composition deterioration [11,32].

During clinical studies, apart from accelerating healing, the most outstanding effect of AM application is rapid wound pain alleviation [17,33,34]. The exact mechanism of analgesic action of AM was not known for a long time and no directly acting component was characterized [35]. Pain relief was thought to be due to the good adhesion of the AM graft to the wound surface, which covers free nerve endings, maintains wound moisture, and releases anti-inflammatory substances that can indirectly relieve pain [35–39].

Recently we have detected and analyzed the levels of *N*-acylethanolamides (NAEs), particularly palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and anandamide (AEA) in various placental tissues, mainly in amniotic and chorionic membrane [40]. We suggested that these NAEs are responsible for pain relief and also have an anti-inflammatory effect. These NAEs were represented in AM in the concentration order of PEA > OEA > AEA, and the concentration of all NAEs increased significantly after 24 hours decontamination with antibiotic solution [40].

NAEs are widely spread endogenous bioactive lipid mediators derived from complex membrane lipids in response to environmental stimuli and play an important role in numerous physiological processes such as immune function, metabolic regulation, pain and inflammation [41]. It has been proposed that PEA, the most abundant NAE in vertebrates [41], accumulates in tissues after injury, and exerts anti-inflammatory, neuroprotective, analgesic and anti-nociceptive effects mainly through the PPAR- α receptor [42,43]. All these PEA properties have been demonstrated in human clinical trials [44–46], including trials on treatment of chronic pain [45,47].

Beside PEA, AEA has also been implicated in possessing anti-nociceptive and anti-inflammatory effects [41,48–50]. Similarly, a role for AEA in wound healing also been suggested [41,49]. OEA has mostly anorexigenic properties [51] and its ability to reduce nociceptive responses and inflammation has been shown [44].

The aim of this study was to monitor dependence of changes in the concentration of PEA, AEA and OEA in AM on the method of tissue storage (cryopreservation and lyophilization) and the

duration of storage, in order to find out whether and for how long individual NAEs persist in the tissue prepared for transplantation purposes.

2. Materials and Methods

2.1. Placenta Retrieval, Decontamination and Amniotic Membrane Preparation

The study followed the Ethics Committee's standards of participating institutions, 1st Medical Faculty of Charles University and General Teaching Hospital (GTH), and University Hospital Motol (UHM), all in Prague, and adhered to the tenets set out in the Declaration of Helsinki. Human placentas obtained at elective Caesarean section from normal pregnancies were obtained with informed consent after delivery at UHM. Only healthy donors, screened for hepatitis B and C, syphilis, HIV and C-reactive protein (< 10 mg/l) were selected.

2.2. Sample Preparation

2.2.1. Fresh and Decontaminated Samples

Nine placentas (P1 – P9, set 1), Figure 1, were used for preparation of fresh and decontaminated samples. Within two hours after the delivery, AM samples were processed and stored using procedures and protocols valid for the preparation of AM for transplantation purposes [52]. Shortly, AM was prepared by manual dissection in the biohazard cabinet. The tissue was washed using sterile saline (0.9% w/v, Fresenius Kabi, Germany), separated from blood clots. Then part of the AM was stretched on a mesh support (Sanatyl; Tylex, Letovice, Czech Republic), and cut to 2 × 2 cm. These fresh specimens (with no decontamination) were immediately used for NAEs analysis. The other part of AM was placed in decontamination solution BASE 128 (Alchimia srl, Italy) for 24 hours at room temperature. Then the 2x2 cm samples were stretched on a mesh support and immediately used for NAE analysis.

2.2.2. Cryopreserved and Lyophilized Samples

The cryopreserved and freeze-dried samples were obtained from nine other placentas (P10 – P18, set 2), Figure 1. Immediately after the delivery, each placenta was placed in decontamination solution BASE 128 for 24 hours at room temperature, then the samples were processed as described above, again based on the preparation of AM for transplantation purposes [52]. The samples were cryopreserved, or freeze-dried (lyophilized).




Figure 1. The schema of amniotic membrane (AM) samples preparation. Fresh and decontaminated AM samples were prepared from placenta 1–9 (set 1), cryopreserved and freeze-dried AM from placenta 10–18 (set 2).

All specimens for cryopreservation were immersed in 40 ml of 1:1 mixture of Dulbecco's Modified Eagle's Medium (c. n. 32430-027, Gibco Life-Technologies, Invitrogen) /glycerol (Glycerolum 85%, Dr. Kulich Pharma s.r.o., Czech Republic), and stored in sterile containers (S245-J, Medfor Products Ltd, Aldershot, UK) at -80°C until the date of NAE analyses.

Lyophilized samples were prepared according to a previously published method [53]. Briefly, AM samples on a mesh carrier (washed with physiological saline) were placed in a sterile Petri dish and freeze-dried (lyophilizer VirTis AdVantage Pro™ Laboratory Benchtop Freeze Dryer, Biotrade Instruments, s. r. o., Prague, Czech Republic). The samples were placed on the pre-frozen lyophilizer shelves (set point: -40°C) and freezing (thermal treatment) was performed for 30 min after cooling to -20°C . Then, the sample was dried in six steps: 1) shelf: -20°C , hold: 360 min.; 2) shelf: 0°C , hold: 360 min.; 3) shelf: 20°C , hold: 360 min.; 4–5) shelf: 30°C , hold: 999 min.; 6) shelf: 30°C , hold: 762 min. All the six steps had the same ramp (10 minutes) and vacuum (200 mTorr) values. After lyophilization, the samples were placed in secondary packaging and stored at room temperature.

AM cryopreserved specimens were stored for 6 ± 1 month (mean 6.2), 12 ± 2 months (mean 11.9 months), 48 ± 6 months (mean 52 months) and 10 years (± 1 year, mean 10.4), freeze-dried samples were stored for six months (± 1 months, mean 6.1), and for one year (± 2 months, mean 1.1). The freeze-dried samples were stored for one year (± 2 months, mean 1.1).

2.3. Sample Preparation and UHPLC/MS of NAEs

All specimens (size 2×2 cm) were used in triplicates. The experiments were performed in duplicates. Fresh and decontaminated AM samples were washed in saline three times for five minutes and removed from mesh support. The same procedure was applied to freeze dried samples, and cryopreserved samples after thawing.

Samples were processed according to a previously published protocol [40]. Briefly, samples were mechanically homogenized in cold acetonitrile (HiPerSolv CHROMANORM, LC-MS grade, Leuven, Belgium) (cut with scissors, 2 minutes). Then, internal standard solution PEA- d_4 (with $\geq 99\%$ deuterium incorporation, Cayman Chemicals, Ann Arbor, MI, US) was added ($10\ \mu\text{l}$, $1\ \mu\text{g/ml}$) to all homogenates. Samples were shaken (4°C and 800 rpm) and then centrifuged (20 min., 15000 g). Supernatants (extracts) were evaporated to dryness in a vacuum centrifuge set at 0°C and re-dissolved in 1 ml of 30% (v/v) methanol (HiPerSolv CHROMANORM, LC-MS grade, Leuven, Belgium) and purified by solid phase extraction following a previously published protocol [40]. Pellets were dried in an evacuated centrifuge (Refrigerated CentriVap Concentrator, Labconco Corporation, Kansas City, MO, US) and weighed. Samples were stored at -80°C until UHPLC/MS.

The UHPLC/MS system consisted of an ExionLC UHPLC AD chromatography system and a QTRAP 6500+ mass spectrometer (both Sciex, Foster City, CA, USA) with an electrospray. Recently published UHPLC/MS method was used [40]. Internal standards PEA- d_4 ($10\ \mu\text{l}$ at $1\ \mu\text{g/ml}$) were used to construct minimally seven-point combined NAEs calibration curves (OEA ($\geq 98\%$) and AEA (MaxSpec standard quality) Cayman Chemicals, Ann Arbor, MI, US; PEA ($\geq 98\%$), Merck, Darmstadt, Germany), constructed for the relative signal intensity of the analyte (related to area of the internal standard). Peak integration, calibration curve construction and determination of analyte concentration were performed using Analyst 1.6.3 (Sciex, Darmstadt, Germany). For each AM sample, the concentration of specific NAEs (PEA, OEA and AEA) was related to the weight of extracted material.

2.4. Immunohistochemistry for PPAR α Receptor

Fluorescent indirect immunohistochemistry [54,55] was used to detect PPAR α receptor in fresh, decontaminated, cryopreserved and freeze-dried AM samples from four placentas. Cryospecimens of human arm skin were used as a positive control [56]. Specimens were washed three times for five minutes in sterile saline and fixed on a mesh support.

A circle with a diameter of ~ 1 cm was cut from the 2×2 cm samples and placed on a plastic holder in which incubation took place. Samples were fixed using 4% paraformaldehyde, and then cell membranes were permeabilized using 0.33% Triton X-100 (Sigma-Aldrich) diluted in PBS.

Primary antibody (mouse monoclonal antibody PPAR α , H-2 clone, Santa Cruz Biotechnology sc-398394, diluted 1:500 in 0.1% bovine serum albumin) was applied overnight at room temperature, then samples were washed and secondary antibody Alexa Fluor 488 goat anti-mouse IgG (A11029, Invitrogen, Frederick, Maryland, USA) was applied overnight at 4 °C and washed three times in PBS. The mesh holder was removed and specimens placed on a slide and mounted with VectaShield-PI (Vector Laboratories, Burlingame, CA, USA). The immunostaining was assessed using a fluorescence microscope (Nikon ECLIPSE Ni-U, Nikon) at $\times 200$ and $\times 400$ magnifications. The images were obtained with VDS CD-1300QF (VDS Vosskühler GmbH, Osnabrück, Germany) camera, and for positivity evaluation image-management software (NIS Elements; Laboratory Imaging, Prague, Czech Republic) was used. The percentage of positive cells was calculated in at least 2 000 cells.

2.5. Statistical Analysis

Each sample was analyzed in triplicate. The resulting average + SD was calculated from 6–9 mean values (depending on the sample) from each triplicate. Mann-Whitney test was used to compare specific NAEs concentrations between individual AM samples: fresh (control), decontaminated (control for all stored samples), and cryopreserved or freeze-dried samples, see Supplementary data, Table S1. P-values less than 0.05 were considered statistically significant. Statistical analysis was performed using GraphPad Prism 8.0 software (La Jolla, CA, USA).

3. Results

3.1. NAE Concentrations in Fresh, Cryopreserved and Freeze-Dried Amniotic Membrane

NAEs were detected in all analyzed samples. The highest levels were measured for PEA. Values of individual NAEs in cryopreserved and freeze-dried samples stored for different time periods were compared with values measured after decontamination as all stored AM were decontaminated during tissue processing. A significant increase in all NAEs values compared to fresh samples was detected after 24 h decontamination. These were used as baseline values for comparison with cryopreserved and freeze-dried samples. The average concentrations of PEA, OEA and AEA are shown in Table 1 and Figure 2. The mean concentration of PEA in all cryopreserved specimens (six months, one, four and 10 years) was significantly lower compared to decontaminated AM, Figure 2A. A different situation was observed for OEA, and AEA, where no significant difference was found after cryopreservation, Figure 2B,C. However, significantly higher values for all NAEs were detected in cryopreserved samples compared to fresh tissue before decontamination, see Supplementary data, Table S2. The concentration of particular NAEs in freeze-dried AM analyzed after one year were almost identical (PEA, AEA), or even higher (OEA) compared to baseline averages (decontaminated AM), but no significant difference was found, Figure 2.

Table 1. Concentrations of palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and anandamide (AEA) (ng/g) in amniotic membrane in fresh, decontaminated (Deco), cryopreserved (Cryo), and freeze-dried (F-Dry) specimens. Cryopreserved samples were stored for six months (m) and for one-, four- and ten-years (y). Freeze-dried samples were stored for one year.

Samples	Fresh	Deco	Cryo 6 m	Cryo 1 y	Cryo 4 y	Cryo 10 y	F-Dry 1 y
PEA (AV)	323.85	1241.76	806.26	812.86	497.16	561.16	1121.76
PEA (SD)	202.68	245.07	485.69	403.27	285.76	248.25	692.50
OEA (AV)	106.56	320.42	314.30	280.56	227.87	293.77	440.25
OEA (SD)	55.68	123.26	175.76	136.40	106.84	127.06	258.60
AEA (AV)	14.87	43.58	43.19	43.70	21.31	39.76	160.00
AEA (SD)	5.82	26.02	32.75	24.09	10.74	14.39	134.99

Data are presented as an average value (AV). SD, standard deviation.




Figure 2. The levels of N-acyl ethanolamines in fresh, decontaminated, cryopreserved and freeze-dried amniotic membranes. The average concentrations of palmitoylethanolamide (PEA) (A), oleoylethanolamide (OEA) (B), and anandamide (AEA) (C) are expressed in ng/g. P-value: $P < 0.05^*$; $P < 0.01^{**}$; $P < 0.001^{***}$; $P < 0.0001^{****}$, m = months, y = years.

3.2. The Detection of PPAR- α Receptor Using Indirect Immunohistochemistry

The PPAR- α receptor was found in all tested tissue. The strong immunostaining was homogenously present through 98–100% of nuclei in the epithelial layer of AM. The positivity was also observed in mesenchymal cells of the fibroblast layer. The nuclear positivity was more diffused in fresh and decontaminated tissue, while more prominent dot signal was present in cryopreserved and freeze-dried samples, see Figure 3.




Figure 3. Expression of PPAR- α receptor in amniotic membrane. Immunostaining in fresh (A), decontaminated (B), cryopreserved (C) and freeze-dried (D) amniotic membrane samples. Strong nuclear staining for PPAR- α receptor (green) was detected in 95 – 100% of epithelial cells (A–D). The nuclear staining was also observed in the mesenchymal cells of underlying fibroblast layer (E). The presence of PPAR- α was confirmed on amniotic membrane cryosections (F). Human cryosections of arm skin were used as a positive control (G). Nuclei were counterstained with propidium-iodide (red). Scale bar represents 10 μ m.

4. Discussion

The main goal of this study was to determine whether the analgesic and anti-inflammatory endogenous lipid mediators NAEs, present in AM allografts persist under standard tissue bank storage conditions. We have shown that there is significant decrease of PEA in cryopreserved AM stored from six months to ten years. No further significant decreases in either PEA, AEA or OEA between baseline levels and cryopreserved or freeze-dried AM allografts stored from six months up to the longest tested period were detected.

The presence of NAEs in placental membranes was first described by Marczylo in 2009, who detected anandamid (AEA) in amniochorionic membrane and placenta [57]. Also, pain relief has been repeatedly described both after the application of AM on the damaged or diseased ocular surface [58,59], and also on the surface of various types of wounds [33,60]. However, only recently has the presence of NAEs been linked to the analgesic effect of AM allografts [40]. In addition to the analgesic effect, NAEs can also participate on nociceptive, anti-inflammatory, and neuroprotective effects [41,44,48–50], which all of them are linked to AM properties receptor [4,22,61].

Previously, we have shown that the content of PEA, AEA and OEA in placental samples is variable, mainly because of the known inter-individual differences between donors, but their concentration can be increased by tissue decontamination [40]. This effect is probably caused by both the production of NAEs by surviving cells in AM and their release from degrading tissue [40]. Results from the first set of placentas (1 – 9), confirmed the increase of all NAEs after 24 h of decontamination with an antibiotic solution. For PEA, the average increase was 3.8-fold, for OEA 3-fold, and for AEA 2.9-fold. This indicates that all tested NAEs react to decontamination in a similar way. Since the decontamination was an integral part of the preparation of all placentas that were used for the second part of the experiment (placentas 10 – 18), the mean concentration of particular NAEs in decontaminated samples then served as baselines.

Although cryopreservation resulted in a significant decrease of PEA after all storage periods, OEA and AEA were not significantly changed. On the other hand, the level of PEA in cryopreserved tissue after different storage time periods was significantly higher compared to the average measured

in fresh, i.e., in non-decontaminated tissue. The only exception was at four years incubation, where the value was higher, but with no statistical significance, see Supplementary data, Table S2. For all NAEs, there was no significant decrease between six months to ten-years storage, which indicates that PEA degradation is more dependent on the freezing or melting process rather than the length of cryopreservation. The decrease of PEA concentrations after cryopreservation can be explained by higher sensitivity of this enzyme compared to OEA or AEA. Another possibility is activation of enzymes degrading NAEs in AM [62].

Due to the six-month quarantine period, after which the allografts are released for transplantation, the most important NAEs values are between the first and fourth year, i.e. in the period during which tissue can be used for grafting before expiration. The cryopreserved and freeze-dried AM allografts are typically stored for between two to five years prior to expiration [4,5].

Very interesting values of NAEs were found after twelve-months storage of freeze-dried AM. The measured concentrations were practically identical to decontaminated tissue (PEA), or even higher (OEA, AEA), although the differences were not significant. Since no longer-preserved freeze-dried tissue was available under the conditions of our tissue bank, it is necessary to verify these data on a larger number of AM samples and also after a longer time period.

Since we noticed a decrease in PEA concentration in cryopreserved samples, we wanted to find out if there is any data available on the analgesic effect of AM depending on its type. To the best of our knowledge, no study has compared the analgesic effect between multiple types of AM. Of the studies where pain was assessed using a pain score, analgesic effect was verified in studies using fresh [16,17], cryopreserved [33,60,63], and air-dried terminally sterilized (gamma irradiation 25 k Gy) [34] AM allografts for various wound treatment.

It has been shown, that NAEs exert their actions via several mechanisms [64], particularly via PPAR- α receptor [42], which is also expressed in the skin [49]. Due to the autocrine secretion of NAEs, our aim was also to confirm PPAR- α receptor expression in tested samples. We found that it remains preserved in all types of AM allograft used regardless of the type and length of storage.

5. Conclusions

We analyzed the content of NAEs in long-term stored AM grafts prepared for grafting and have shown that in cryopreserved tissue, PEA, OEA and AEA remain in relatively high concentrations even after four years of storage. This means that the above described features of all three NAEs may be involved in positive analgesic and anti-inflammatory effects of AM allografts during wound healing.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Supplementary data, Table S1, Supplementary data, Table S1.

Author Contributions: Conceptualization, K.J. and V.V.; methodology, I.S, V.V., N.S.; investigation, I.S, V.V., N.S., A.S., C.J.J.; resources, K.J., J.B.; statistics: S.S.; writing—original draft preparation, I.S, K.J., N.S., V.V.; writing—review and editing, C.J.J.; K.J., V.V.; visualization, S.S., N.S.; funding acquisition, K.J. All authors have read and agreed to the published version of the manuscript.

Funding: This work was founded by the Ministry of Health of the Czech Republic, grant number NV18-08-00106, and by Ministry of Education, Youth and Sports the project BBMRI.cz, reg. no. LM202303. Institutional support (Charles University, Prague) was provided by program Cooperatio: Medical Diagnostics and Basic Medical Sciences (KJ).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the General University Hospital and the First Faculty of Medicine of Charles University, Prague, Czech Republic (No.38/17, Grant AZV VES2018 1. LF UK, 31/05/2017).

Informed Consent Statement: Informed consent was obtained from all placenta donors (No.38/17, Grant AZV VES2018 1. LF UK, 31/05/2017).

Acknowledgments: The authors are thankful to Dr. Denisa Nemetova, Mrs. Dagmar Hrabankova (Department of Transplantation and Tissue Bank, Motol University Hospital), MD. Viera Vesela and MD. Joao Victor Cabral

(Institute of Biology and Medical Genetics, Charles University, Prague) for technical assistance with amniotic membrane preparation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nejad, A.R.; Hamidieh, A.A.; Amirkhani, M.A.; Sisakht, M.M. Update review on five top clinical applications of human amniotic membrane in regenerative medicine. *Placenta* **2021**, *103*, 104–119, doi:10.1016/j.placenta.2020.10.026.
2. Liu, Q.-W.; Huang, Q.-M.; Wu, H.-Y.; Zuo, G.-S.-L.; Gu, H.-C.; Deng, K.-Y.; Xin, H.-B. Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells. *International Journal of Molecular Sciences* **2021**, *22*, doi:10.3390/ijms22020970.
3. Weidinger, A.; Poženel, L.; Wolbank, S.; Banerjee, A. Sub-Regional Differences of the Human Amniotic Membrane and Their Potential Impact on Tissue Regeneration Application. *Frontiers in Bioengineering and Biotechnology* **2021**, *8*, doi:10.3389/fbioe.2020.613804.
4. Malhotra, C.; Jain, A.K. Human amniotic membrane transplantation: Different modalities of its use in ophthalmology. *World J Transplant* **2014**, *4*, 111–121, doi:10.5500/wjt.v4.i2.111.
5. Jirsova, K.; Jones, G.L.A. Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting—a review. *Cell and Tissue Banking* **2017**, *18*, 193–204, doi:10.1007/s10561-017-9618-5.
6. Anselmo, D.S.; McGuire, J.B.; Love, E.; Vlahovic, T. Application of Viable Cryopreserved Human Placental Membrane Grafts in the Treatment of Wounds of Diverse Etiologies: A Case Series. *Wounds* **2018**, *30*, 57–61.
7. Farivar, B.S.; Toursavadkahi, S.; Monahan, T.S.; Sharma, J.; Ucuzian, A.A.; Kundi, R.; Sarkar, R.; Lal, B.K. Prospective study of cryopreserved placental tissue wound matrix in the management of chronic venous leg ulcers. *J Vasc Surg Venous Lymphat Disord* **2019**, *7*, 228–233, doi:10.1016/j.jvsv.2018.09.016.
8. Lopez Martinez, J.A.; Rodriguez Valiente, M.; Fuente-Mora, C.; Garcia-Hernandez, A.M.; Canovas Sanchis, S.; Fernandez Pascual, C.J. Use of cryopreserved human amniotic membrane in the treatment of skin ulcers secondary to calciphylaxis. *Dermatol Ther* **2021**, *34*, e14769, doi:10.1111/dth.14769.
9. Game, F.; Gray, K.; Davis, D.; Sherman, R.; Chokkalingam, K.; Connan, Z.; Fakis, A.; Jones, M. The effectiveness of a new dried human amnion derived membrane in addition to standard care in treating diabetic foot ulcers: A patient and assessor blind, randomised controlled pilot study. *Int Wound J* **2021**, *18*, 692–700, doi:10.1111/iwj.13571.
10. Mimouni, M.; Trinh, T.; Sorkin, N.; Cohen, E.; Santaella, G.; Rootman, D.S.; Slomovic, A.R.; Chan, C.C. Sutureless dehydrated amniotic membrane for persistent epithelial defects. *Eur J Ophthalmol* **2021**, 11206721211011354, doi:10.1177/11206721211011354.
11. Serena, T.E.; Orgill, D.P.; Armstrong, D.G.; Galiano, R.D.; Glat, P.M.; Carter, M.J.; Kaufman, J.P.; Li, W.W.; Zelen, C.M. A Multicenter, Randomized, Controlled, Clinical Trial Evaluating Dehydrated Human Amniotic Membrane in the Treatment of Venous Leg Ulcers. *Plast Reconstr Surg* **2022**, *150*, 1128–1136, doi:10.1097/PRS.00000000000009650.
12. Allen, C.L.; Clare, G.; Stewart, E.A.; Branch, M.J.; McIntosh, O.D.; Dadhwal, M.; Dua, H.S.; Hopkinson, A. Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing. *PLoS One* **2013**, *8*, e78441, doi:10.1371/journal.pone.0078441.
13. Morkin, M.I.; Hamrah, P. Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain. *Ocul Surf* **2018**, *16*, 132–138, doi:10.1016/j.jtos.2017.10.003.
14. Insausti, C.L.; Alcaraz, A.; García-Vizcaino, E.M.; Mrowiec, A.; López-Martínez, M.C.; Blanquer, M.; Piñero, A.; Majado, M.J.; Moraleda, J.M.; Castellanos, G.; et al. Amniotic membrane induces epithelialization in massive posttraumatic wounds. *Wound Repair Regen*. **2010**, *18*, 368–377, doi:10.1111/j.1524-475X.2010.00604.x.

15. Mao, Y.; Hoffman, T.; Dhall, S.; Singal, A.; Sathyamoorthy, M.; Danilkovitch, A.; Kohn, J. Endogenous viable cells in lyopreserved amnion retain differentiation potential and anti-fibrotic activity in vitro. *Acta Biomater.* **2019**, *94*, 330-339, doi:10.1016/j.actbio.2019.06.002.
16. Alsina-Gibert, M.; Pedregosa-Fauste, S. Amniotic membrane transplantation in the treatment of chronic lower limb ulcers. *Actas Dermosifiliogr* **2012**, *103*, 608-613, doi:10.1016/j.ad.2012.01.010.
17. Eskandarlou, M.; Azimi, M.; Rabiee, S.; Seif Rabiee, M.A. The Healing Effect of Amniotic Membrane in Burn Patients. *World J Plast Surg* **2016**, *5*, 39-44.
18. Navas, A.; Magaña-Guerrero, F.S.; Domínguez-López, A.; Chávez-García, C.; Partido, G.; Graue-Hernández, E.O.; Sánchez-García, F.J.; Garfias, Y. Anti-Inflammatory and Anti-Fibrotic Effects of Human Amniotic Membrane Mesenchymal Stem Cells and Their Potential in Corneal Repair. *STEM CELLS Translational Medicine* **2018**, *7*, 906-917, doi:10.1002/sctm.18-0042.
19. King, A.E.; Paltoo, A.; Kelly, R.W.; Sallenave, J.M.; Bocking, A.D.; Challis, J.R.G. Expression of Natural Antimicrobials by Human Placenta and Fetal Membranes. *Placenta* **2007**, *28*, 161-169, doi:10.1016/j.placenta.2006.01.006.
20. Franco, G.R.; de Carvalho, A.F.; Kroon, E.G.; Lovagie, S.; Werenne, J.; Golgher, R.R.; Ferreira, P.C.P.; Bonjardim, C.A. Biological Activities of a Human Amniotic Membrane Interferon. *Placenta* **1999**, *20*, 189-196, doi:10.1053/plac.1998.0364.
21. Koob, T.J.; Lim, J.J.; Massee, M.; Zabek, N.; Rennert, R.; Gurtner, G.; Li, W.W. Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. *Vascular Cell* **2014**, *6*, doi:10.1186/2045-824x-6-10.
22. Duan-Arnold, Y.; Uveges, T.E.; Gyurdieva, A.; Johnson, A.; Danilkovitch, A. Angiogenic Potential of Cryopreserved Amniotic Membrane Is Enhanced Through Retention of All Tissue Components in Their Native State. *Adv Wound Care (New Rochelle)* **2015**, *4*, 513-522, doi:10.1089/wound.2015.0638.
23. Shao, C.; Sima, J.; Zhang, S.X.; Jin, J.; Reinach, P.; Wang, Z.; Ma, J.-x. Suppression of Corneal Neovascularization by PEDF Release from Human Amniotic Membranes. *Invest. Ophthalmol. Vis. Sci.* **2004**, *45*, doi:10.1167/iovs.03-0882.
24. Yin, L.; Pi, Y.L. Effect of amnion membrane transplantation on corneal neovascularization in 10 patients with alkali burn. *Int J Ophthalmol* **2011**, *4*, 110-111, doi:10.3980/j.issn.2222-3959.2011.01.25.
25. Kim, J.C.; Tseng, S.C.G. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. *Korean J. Ophthalmol.* **1995**, *9*, doi:10.3341/kjo.1995.9.1.32.
26. Lee, S.H.; Tseng, S.C. Amniotic membrane transplantation for persistent epithelial defects with ulceration. *Am J Ophthalmol* **1997**, *123*, 303-312, doi:10.1016/s0002-9394(14)70125-4.
27. Wang, W. Lyophilization and development of solid protein pharmaceuticals. *Int. J. Pharm.* **2000**, *203*, 1-60, doi:10.1016/s0378-5173(00)00423-3.
28. Lim, L.S.; Poh, R.W.; Riau, A.K.; Beuerman, R.W.; Tan, D.; Mehta, J.S. Biological and ultrastructural properties of acelagraft, a freeze-dried gamma-irradiated human amniotic membrane. *Arch Ophthalmol* **2010**, *128*, 1303-1310, doi:10.1001/archophthalmol.2010.222.
29. Paolin, A.; Trojan, D.; Leonardi, A.; Mellone, S.; Volpe, A.; Orlandi, A.; Cogliati, E. Cytokine expression and ultrastructural alterations in fresh-frozen, freeze-dried and γ -irradiated human amniotic membranes. *Cell Tissue Banking* **2016**, *17*, 399-406, doi:10.1007/s10561-016-9553-x.
30. McQuilling, J.P.; Vines, J.B.; Kimmerling, K.A.; Mowry, K.C. Proteomic Comparison of Amnion and Chorion and Evaluation of the Effects of Processing on Placental Membranes. *Wounds* **2017**, *29*, E36-E40.
31. Johnson, A.; Gyurdieva, A.; Dhall, S.; Danilkovitch, A.; Duan-Arnold, Y. Understanding the Impact of Preservation Methods on the Integrity and Functionality of Placental Allografts. *Ann Plast Surg* **2017**, *79*, 203-213, doi:10.1097/SAP.0000000000001101.

32. DiDomenico, L.A.; Orgill, D.P.; Galiano, R.D.; Serena, T.E.; Carter, M.J.; Kaufman, J.P.; Young, N.J.; Jacobs, A.M.; Zelen, C.M. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. *Int Wound J* **2018**, *15*, 950-957, doi:10.1111/iwj.12954.
33. Kadkhoda, Z.; Tavakoli, A.; Chokami Rafiei, S.; Zolfaghari, F.; Akbari, S. Effect of Amniotic Membrane Dressing on Pain and Healing of Palatal Donor Site: A Randomized Controlled Trial. *Int J Organ Transplant Med* **2020**, *11*, 55-62.
34. Vaheb, M.; Kohestani, B.M.; Karrabi, M.; Khosrojerdi, M.; Khajeh, M.; Shahrestanaki, E.; Sahebkar, M. Evaluation of Dried Amniotic Membrane on Wound Healing at Split-Thickness Skin Graft Donor Sites: A Randomized, Placebo-Controlled, Double-blind Trial. *Adv Skin Wound Care* **2020**, *33*, 636-641, doi:10.1097/01.ASW.0000695752.52235.e3.
35. Tseng, S.C. HC-HA/PTX3 Purified From Amniotic Membrane as Novel Regenerative Matrix: Insight Into Relationship Between Inflammation and Regeneration. *Invest Ophthalmol Vis Sci* **2016**, *57*, ORSFh1-8, doi:10.1167/iovs.15-17637.
36. Talmi, Y.P.; Finkelstein, Y.; Zohar, Y. Use of human amniotic membrane as a biologic dressing. *Eur. J. Plast. Surg.* **1990**, *13*, doi:10.1007/bf00236370.
37. Kesting, M.R.; Wolff, K.D.; Hohlweg-Majert, B.; Steintraesser, L. The role of allogenic amniotic membrane in burn treatment. *J Burn Care Res* **2008**, *29*, 907-916, doi:10.1097/BCR.0b013e31818b9e40.
38. Liu, J.; Sheha, H.; Fu, Y.; Liang, L.; Tseng, S.C. Update on amniotic membrane transplantation. *Expert Rev Ophthalmol* **2010**, *5*, 645-661, doi:10.1586/eop.10.63.
39. ElHeneidy, H.; Omran, E.; Hieneedy, H.; Halwagy, A.; Al-Inany, H.; Al-Ansary, M.; Gad, A. Amniotic membrane can be a valid source for wound healing. *International Journal of Women's Health* **2016**, Volume 8, 225-231, doi:10.2147/ijwh.S96636.
40. Svobodova, A.; Vrkoslav, V.; Smeringaiova, I.; Jirsova, K. Distribution of an analgesic palmitoylethanolamide and other N-acylethanolamines in human placental membranes. *PLOS One* **2023**, *18*, e0279863, doi:10.1371/journal.pone.0279863.
41. Esposito, E.; Cuzzocrea, S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. *Mini Rev Med Chem* **2013**, *13*, 237-255.
42. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor- α mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol Pharmacol* **2005**, *67*, 15-19, doi:10.1124/mol.104.006353.
43. Esposito, E.; Cuzzocrea, S. Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries. *CNS & Neurological Disorders - Drug Targets* **2013**, *12*, 55-61, doi:10.2174/1871527311312010010.
44. Suardiaz, M.; Estivill-Torrus, G.; Goicoechea, C.; Bilbao, A.; Rodriguez de Fonseca, F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. *Pain* **2007**, *133*, 99-110, doi:10.1016/j.pain.2007.03.008.
45. Gatti, A.; Lazzari, M.; Gianfelice, V.; Di Paolo, A.; Sabato, E.; Sabato, A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. *Pain Med* **2012**, *13*, 1121-1130, doi:10.1111/j.1526-4637.2012.01432.x.
46. Di Paola, R.; Impellizzeri, D.; Fusco, R.; Cordaro, M.; Siracusa, R.; Crupi, R.; Esposito, E.; Cuzzocrea, S. Ultramicronized palmitoylethanolamide (PEA-um((R))) in the treatment of idiopathic pulmonary fibrosis. *Pharmacol Res* **2016**, *111*, 405-412, doi:10.1016/j.phrs.2016.07.010.
47. Paladini, A.; Fusco, M.; Cenacchi, T.; Schievano, C.; Piroli, A.; Varrassi, G. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. *Pain Physician* **2016**, *19*, 11-24.
48. Di Marzo, V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. *Biochim Biophys Acta* **1998**, *1392*, 153-175, doi:10.1016/s0005-2760(98)00042-3.

49. Correia-Sa, I.B.; Carvalho, C.M.; Serrao, P.V.; Loureiro, A.I.; Fernandes-Lopes, C.; Marques, M.; Vieira-Coelho, M.A. A new role for anandamide: defective link between the systemic and skin endocannabinoid systems in hypertrophic human wound healing. *Sci Rep* **2020**, *10*, 11134, doi:10.1038/s41598-020-68058-3.
50. Ruhl, T.; Corsten, C.; Beier, J.P.; Kim, B.S. The immunosuppressive effect of the endocannabinoid system on the inflammatory phenotypes of macrophages and mesenchymal stromal cells: a comparative study. *Pharmacol Rep* **2021**, *73*, 143-153, doi:10.1007/s43440-020-00166-3.
51. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; Rodriguez De Fonseca, F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; et al. Oleyethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature* **2003**, *425*, 90-93, doi:10.1038/nature01921.
52. Svobodova, A.; Horvath, V.; Smeringaiova, I.; Cabral, J.V.; Zemlickova, M.; Fiala, R.; Burkert, J.; Nemetova, D.; Stadler, P.; Lindner, J.; et al. The healing dynamics of non-healing wounds using cryo-preserved amniotic membrane. *Int Wound J* **2022**, *19*, 1243-1252, doi:10.1111/iwj.13719.
53. Dhall, S.; Sathyamoorthy, M.; Kuang, J.Q.; Hoffman, T.; Moorman, M.; Lerch, A.; Jacob, V.; Sinclair, S.M.; Danilkovitch, A. Properties of viable lyopreserved amnion are equivalent to viable cryopreserved amnion with the convenience of ambient storage. *PLoS One* **2018**, *13*, e0204060, doi:10.1371/journal.pone.0204060.
54. Merjava, S.; Neuwirth, A.; Tanzerova, M.; Jirsova, K. The spectrum of cytokeratins expressed in the adult human cornea, limbus and perilimbal conjunctiva. *Histol Histopathol* **2011**, *26*, 323-331, doi:10.14670/HH-26.323.
55. Trosan, P.; Cabral, J.V.; Smeringaiova, I.; Studeny, P.; Jirsova, K. Interleukin-13 increases the stemness of limbal epithelial stem cells cultures. *PLoS One* **2022**, *17*, e0272081, doi:10.1371/journal.pone.0272081.
56. Trivedi, N.R.; Cong, Z.; Nelson, A.M.; Albert, A.J.; Rosamilia, L.L.; Sivarajah, S.; Gilliland, K.L.; Liu, W.; Mauger, D.T.; Gabbay, R.A.; et al. Peroxisome proliferator-activated receptors increase human sebum production. *J Invest Dermatol* **2006**, *126*, 2002-2009, doi:10.1038/sj.jid.5700336.
57. Lam, P.M.; Marczylo, T.H.; Konje, J.C. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* **2010**, *398*, 2089-2097, doi:10.1007/s00216-010-4103-z.
58. Georgiadis, N.S.; Ziakas, N.G.; Boboridis, K.G.; Terzidou, C.; Mikropoulos, D.G. Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. *Clin Exp Ophthalmol* **2008**, *36*, 130-135, doi:10.1111/j.1442-9071.2008.01696.x.
59. Sharma, N.; Singh, D.; Maharana, P.K.; Kriplani, A.; Velpandian, T.; Pandey, R.M.; Vajpayee, R.B. Comparison of Amniotic Membrane Transplantation and Umbilical Cord Serum in Acute Ocular Chemical Burns: A Randomized Controlled Trial. *Am J Ophthalmol* **2016**, *168*, 157-163, doi:10.1016/j.ajo.2016.05.010.
60. Loeffelbein, D.J.; Rohleder, N.H.; Eddicks, M.; Baumann, C.M.; Stoeckelhuber, M.; Wolff, K.D.; Drecoll, E.; Steinstraesser, L.; Hennerbichler, S.; Kesting, M.R. Evaluation of human amniotic membrane as a wound dressing for split-thickness skin-graft donor sites. *Biomed Res Int* **2014**, *2014*, 572183, doi:10.1155/2014/572183.
61. Maskin, S.L. Successful reversal of neuropathic eye pain by treatment of occult ocular surface disease: Case series and implications. *Am J Ophthalmol Case Rep.* **2022**, *27*, 101662, doi: 10.1016/j.ajoc.2022.101662.
62. Park B.; Gibbons H.M.; Mitchell M.D.; Glassa M. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. *Placenta* **2003**, *24*, 473-8. doi: 10.1053/plac.2002.0926. Corrected and republished in: *Placenta*. 2003 Nov;24(10):990-5. PMID: 12744923.

63. Zidan, S.M.; Eleowa, S.A.; Nasef, M.A.; Abd-Almuktader, M.A.; Elbatawy, A.M.; Borhamy, A.G.; Aboliela, M.A.; Ali, A.M.; Algamal, M.R. Maximizing the safety of glycerol preserved human amniotic membrane as a biological dressing. *Burns* **2015**, *41*, 1498-1503, doi:10.1016/j.burns.2015.03.009.
64. Rankin, L.; Fowler, C.J. The Basal Pharmacology of Palmitoylethanolamide. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21217942.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.